Turning Point Therapeutics, Inc. (NASDAQ:TPTX)
Industry: Healthcare

OFF LIST - 1699 consecutive market days: OFF LIST as of 09/04/2009 Through 11/14/2016

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.

Current Quote*
Last: $75.990
Change: 0.000
Book: $3.334
Volume: 1,109,486

As Of: 08/16 13:00 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol TPTX

  • No BuyIns.Net Alerts Available for TPTX

Graphs for TPTX


3 Month Graph


6 Month Graph


1 Year Graph